Mirror sandwich SERS substrates (M3S) were used to monitor the kinetics of Bacillus subtilis endospore germination. The sandwich configuration of the substrates allows real-time observation of germination in samples that contained only several hundred endospores. The enhancement provided by the substrates is attributed to the enhanced local electromagnetic field that originates from coupling between the Ag nanoparticles and the underlying metal film as well as from coupling between the Ag nanoparticles themselves. The germination kinetics at varying concentrations of l-alanine and different temperatures were studied by monitoring the intensity and growth of the Raman peak at 1010 cm(-1), which is characteristic of dipicolinic acid. A total of four concentrations (50, 75, 100, and 150 mM) of l-alanine and three different temperatures (30, 37, and 55 degrees C) were investigated.

A method for monitoring DPA release from a single germinating Bacillus subtilis endospore is reported. High S/N ratio SERS spectra were obtained with excitation power 3 mW at 647.1 nm and 1 min spectral collection times. The method is proof-of-principle for the SERS detection limit at the single spore level. This represents a 100- to 1000-fold improvement over previously reported detection limits for SERS-based measurements of DPA in endospores.

Anti-angiogenic therapies are effective for the treatment of cancer, a variety of ocular diseases, and have potential benefits in cardiovascular disease, arthritis, and psoriasis. We have previously shown that anthrax protective antigen (PA), a non-pathogenic component of anthrax toxin, is an inhibitor of angiogenesis, apparently as a result of interaction with the cell surface receptors capillary morphogenesis gene 2 (CMG2) protein and tumor endothelial marker 8 (TEM8). Hence, molecules that bind the anthrax toxin receptors may be effective to slow or halt pathological vascular growth. Here we describe development and testing of an effective homogeneous steady-state fluorescence resonance energy transfer (FRET) high throughput screening assay designed to identify molecules that inhibit binding of PA to CMG2. Molecules identified in the screen can serve as potential lead compounds for the development of anti-angiogenic and anti-anthrax therapies. The assay to screen for inhibitors of this protein–protein interaction is sensitive and robust, with observed Z' values as high as 0.92. Preliminary screens conducted with a library of known bioactive compounds identified tannic acid and cisplatin as inhibitors of the PA-CMG2 interaction. We have confirmed that tannic acid both binds CMG2 and has anti-endothelial properties. In contrast, cisplatin appears to inhibit PA-CMG2 interaction by binding both PA and CMG2, and observed cisplatin anti-angiogenic effects are not mediated by interaction with CMG2. This work represents the first reported high throughput screening assay targeting CMG2 to identify possible inhibitors of both angiogenesis and anthrax intoxication.

Tumor marker endothelial 8 (TEM8) is a receptor for the Protective Antigen (PA) component of anthrax toxin. TEM8 is upregulated on endothelial cells lining the blood vessels within tumors, compared to normal blood vessels. A number of studies have demonstrated a pivotal role for TEM8 in developmental and tumor angiogenesis. We have also shown that targeting the anthrax receptors with a mutated form of PA inhibits angiogenesis and tumor formation in vivo. Here we describe the development and testing of a high-throughput fluorescence resonance energy transfer assay to identify molecules that strongly inhibit the interaction of PA and TEM8. The assay we describe is sensitive and robust, with a Z-prime value of 0.8. A preliminary screen of 2310 known bioactive library compounds identified ebselen and thimerosal as inhibitors of the TEM8-PA interaction. These molecules each contain a cysteine-reactive transition metal, and complimentary studies indicate that their inhibition of interaction is due to modification of a cysteine residue in the TEM8 extracellular domain. This is the first demonstration of a high-throughput screening assay that identifies inhibitors of TEM8, with potential application for anti-anthrax and anti-angiogenic diseases.

No abstract